Genprex, Inc. Banner Image

Genprex, Inc.

  • Ticker GNPX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Genprex, Inc. Logo Image
  • 1-10 Employees
  • Based in Austin, Texas
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutionsMore and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells.
4.8 / 5.0 (168)

Genprex, Inc. reports have an aggregate usefulness score of 4.8 based on 168 reviews.

Genprex, Inc.

Most Recent Annual Report

Genprex, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Genprex, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!